Axsome Therapeutics (NASDAQ:AXSM) Upgraded to Hold at BidaskClub

Axsome Therapeutics (NASDAQ:AXSM) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Friday, BidAskClub reports.

AXSM has been the topic of several other reports. Piper Jaffray Companies reaffirmed a “buy” rating and set a $125.00 price objective on shares of Axsome Therapeutics in a report on Monday, December 16th. ValuEngine downgraded shares of Axsome Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 3rd. LADENBURG THALM/SH SH reaffirmed a “buy” rating and set a $165.00 price objective (up from $139.00) on shares of Axsome Therapeutics in a report on Tuesday, January 14th. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price objective on shares of Axsome Therapeutics in a report on Monday, March 16th. Finally, Zacks Investment Research downgraded shares of Axsome Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, March 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $108.11.

NASDAQ AXSM opened at $63.54 on Friday. The company has a market cap of $2.36 billion, a PE ratio of -31.77 and a beta of 3.26. Axsome Therapeutics has a 52 week low of $12.76 and a 52 week high of $109.94. The company has a quick ratio of 9.00, a current ratio of 9.00 and a debt-to-equity ratio of 0.10. The firm’s 50-day simple moving average is $78.33 and its two-hundred day simple moving average is $57.25.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.71) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.23). As a group, equities research analysts anticipate that Axsome Therapeutics will post -2.34 EPS for the current year.

Several institutional investors have recently made changes to their positions in the company. Total Clarity Wealth Management Inc. purchased a new stake in shares of Axsome Therapeutics in the fourth quarter worth about $25,000. Barber Financial Group Inc. purchased a new stake in shares of Axsome Therapeutics in the fourth quarter worth about $258,000. Geode Capital Management LLC lifted its holdings in shares of Axsome Therapeutics by 7.1% in the fourth quarter. Geode Capital Management LLC now owns 368,021 shares of the company’s stock worth $38,038,000 after buying an additional 24,385 shares in the last quarter. Brinker Capital Inc. purchased a new stake in shares of Axsome Therapeutics in the fourth quarter worth about $402,000. Finally, Profund Advisors LLC purchased a new stake in shares of Axsome Therapeutics in the fourth quarter worth about $277,000. 60.07% of the stock is currently owned by hedge funds and other institutional investors.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder.

Further Reading: Certificate of Deposit (CD) For Risk Adverse Investors?

Analyst Recommendations for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.